Australasian Journal of Neuroscience最新文献_第4页

Huntington’s Disease: A Nursing Perspective 亨廷顿舞蹈症:护理的视角

Australasian Journal of Neuroscience Pub Date : 2021-10-01 DOI: 10.21307/ajon-2021-007

Sarah V Samperi, P. Kwong, Terence McGill, D. Tsui

引用次数: 0

Differentiating Electrolyte and Fluid Disorders 鉴别电解质和体液紊乱

Australasian Journal of Neuroscience Pub Date : 2021-10-01 DOI: 10.21307/ajon-2021-006

D. Lear, Leigh H. Bruce

{"title":"Differentiating Electrolyte and Fluid Disorders","authors":"D. Lear, Leigh H. Bruce","doi":"10.21307/ajon-2021-006","DOIUrl":"https://doi.org/10.21307/ajon-2021-006","url":null,"abstract":"Abstract Vasopressin or anti-diuretic hormone (ADH) is a nonapeptide that is synthesized in the hypothalamus and plays an important role in the control of the body’s osmotic balance, blood pressure regulation and kidney function. ADH induces expression of water transport proteins in the late distal tubule and collecting duct to increase water re-absorption. ADH is produced by neurons within the supraoptic nuclei of the hypothalamus, stored in secretary vesicles and transported through the hypothalamic-hypophyseal tract and released in the posterior pituitary. The secreted hormones then enter nearby fenestrated capillaries where they enter the body’s systemic circulation. These neurons express osmo receptors that are responsive to blood osmolarity and respond to changes as little as 2 mOsm/L. Therefore slight elevations in osmolarity result in secretion of ADH. ADH acts in the kidneys to increase water re-absorption, thus returning the osmolarity to baseline. ADH is also secreted in times of hypovolaemia. Decreased arterial blood volume is sensed by bar receptors in the left atrium, carotid artery and aortic arch and the signal transported to the vagus nerve which directly stimulates the release of ADH. ADH then promotes water re-absorption in the kidneys to increase effective arterial blood volume and increase blood pressure to maintain tissue perfusion. Osmolarity and volume status are the two greatest factors that affect ADH secretion. There are three pathologic states related to ADH.","PeriodicalId":32533,"journal":{"name":"Australasian Journal of Neuroscience","volume":"34 1","pages":"15 - 17"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84934418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2020 Annual Demographic Survey of Parkinson’s Disease and Movement Disorder Nurse Specialists 2020年帕金森病和运动障碍护士专家年度人口调查

Australasian Journal of Neuroscience Pub Date : 2021-05-01 DOI: 10.21307/ajon-2021-003

S. Williams, D. Tsui, Dr Melanie Zeppel

引用次数: 1

The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2 贝伐单抗治疗2型神经纤维瘤病相关前庭神经鞘瘤的疗效

Australasian Journal of Neuroscience Pub Date : 2021-05-01 DOI: 10.21307/AJON-2021-002

S. Ardern–Holmes, Cassandra White, Sarita Bahure, Simon So, G. McCowage, E. Hovey, S. Troon, P. de Souza, J. Simes, M. Slancar, M. Dexter, M. Wong

{"title":"The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2","authors":"S. Ardern–Holmes, Cassandra White, Sarita Bahure, Simon So, G. McCowage, E. Hovey, S. Troon, P. de Souza, J. Simes, M. Slancar, M. Dexter, M. Wong","doi":"10.21307/AJON-2021-002","DOIUrl":"https://doi.org/10.21307/AJON-2021-002","url":null,"abstract":"Abstract Introduction: We describe an Australian experience of infusional bevacizumab for vestibular schwannoma (VS) in neurofibromatosis type 2 patients, with specific focus on 3-dimensional tumour volume and audiometry. Method: Data was pooled from patients with symptomatic or progressive VS from 2009 to April 2018. Tumours were assessed as total volume per patient. Bevacizumab infusions were administered every 2-4 weeks. 3-D volumetric response (cm3) was determined through serial magnetic resonance imaging, at baseline and at 3-6-month intervals, until cessation of infusions following progression or prior to surgery. Volumetric response was defined as a reduction of volume ³ 20%, from baseline. Patients underwent interval pure tone audiometry. A decrease in the average pure tone analyses by 10dB indicated response. Results: Twenty-one VS tumours were identified in eleven patients. Median age was 26 (range 13 – 67yr). Average baseline tumour volume was 14.17cm3 (range 1.45cm3 - 38.51cm3). Tumour volume reduction >20% was shown in 7/11 patients (64%), indicating partial response, 2/11 (18%) patients showed stable disease, and 2/11 (18%) progressed. Average percentage tumour volume change was +4.45% from baseline (range -57% to 241%). 16 individual ears were tested, 3/16 (19%) of ears showed an average decibel reduction of 10dB or more, indicating response (average change 2.5dB, range -36dB to 81dB). 10/16 (63%) showed stable hearing, and 3/16 (19%) showed hearing deterioration. Conclusion: Bevacizumab is a useful agent for reducing tumour volume and improving hearing losses due to vestibular schwannoma in neurofibromatosis type 2 patients. These results reflect results described from the United Kingdom and United States.","PeriodicalId":32533,"journal":{"name":"Australasian Journal of Neuroscience","volume":"8 1","pages":"5 - 14"},"PeriodicalIF":0.0,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81900053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

2020 to 2021 and Beyond.: The Strength, Vision and Resilience of Workforces 2020年至2021年及以后。:劳动力的力量、愿景和弹性

Australasian Journal of Neuroscience Pub Date : 2021-05-01 DOI: 10.21307/ajon-2021-001a

Linda Nichols

引用次数: 1

2020 Annual Demographic Survey of Parkinson’s Disease and Movement Disorder Nurse Specialists 2020年帕金森病和运动障碍护士专家年度人口调查

Australasian Journal of Neuroscience Pub Date : 2021-05-01 DOI: 10.21307/AJON-2021-001B

Sue Williams, D. Tsui

引用次数: 2

On track to the stomach! ! Cortrak® for the insertion of nasogastric tubes amongst neuroscience patients – how effective is it? 对胃有好处!！ Cortrak®用于神经科学患者的鼻胃管插入-效果如何?

Australasian Journal of Neuroscience Pub Date : 2020-10-01 DOI: 10.21307/ajon-2020-008

C. Woon

引用次数: 0

Epilepsy Surgery: A Paediatric Perspective 癫痫外科:儿科视角

Australasian Journal of Neuroscience Pub Date : 2020-10-01 DOI: 10.21307/ajon-2020-007

Lauren Bollard, E. Moore, Rebecca Paff

引用次数: 0

Oral Care for Neuroscience patients in New Zealand – A national survey 新西兰神经科学患者的口腔护理-一项全国性调查

Australasian Journal of Neuroscience Pub Date : 2020-05-01 DOI: 10.21307/ajon-2020-002

C. Woon

{"title":"Oral Care for Neuroscience patients in New Zealand – A national survey","authors":"C. Woon","doi":"10.21307/ajon-2020-002","DOIUrl":"https://doi.org/10.21307/ajon-2020-002","url":null,"abstract":"Abstract Aims: To understand the experience and knowledge of neuroscience nurses working in acute ward settings in New Zealand regarding oral care. To determine what educational requirements were needed to standardise oral care. Data sources: A systematic review of articles was conducted using Cinahl, PubMed, Cochrane and Google scholar between 2007-2019. Methods: An online survey using Survey Monkey with three out of five units participating from the north and South Island of New Zealand using qualitative and quantitative data. Results: 34% of nurses completed the survey from three different neuroscience wards. Oral hygiene education was provided to the majority of respondents during their initial nursing training, however this was considered inadequate and most nurses did not receive oral hygiene education since their training. It was considered that there was a lack of oral care assessment tools and guidelines available in New Zealand. A lack of evidence-based practice existed. Therefore, inconsistencies over products and frequency of care was problematic. Barriers to effective oral care included the uncooperative patient, lack of access to the mouth and a perceived lack of time to provide oral care. Conclusion: The experience and knowledge of neuroscience nurses in this study was varied. An opportunity existed to implement an oral assessment tool and guideline which could improve the oral care of the neuroscience patient and standardize care throughout New Zealand. Oral hygiene education should be provided and available for nursing students, registered nurses, health care assistants, patients and family to ensure consistent effective oral care. Impact: As a result of this study, a guideline and assessment flowchart were created with an online e-learning experience. This was distributed to a number of hospitals nationwide to ensure standardization of care across all neuroscience wards.","PeriodicalId":32533,"journal":{"name":"Australasian Journal of Neuroscience","volume":"70 1","pages":"10 - 22"},"PeriodicalIF":0.0,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77265694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2020 The Year of the Nurse 2020年是护士年

Australasian Journal of Neuroscience Pub Date : 2020-05-01 DOI: 10.21307/ajon-2020-000b

C. Woon

引用次数: 0